GlaxoSmithKline, the manufacturer of the Breo Ellipta inhaler, has been accused of anticompetitive practices to block generic competition and maintain inflated prices. The lawsuit claims GSK retired branded inhalers and replaced them with newer products granted new patents, extending its exclusivity. This alleged “device hopping” tactic allowed GSK to charge higher prices, impacting patients. If you’d like to learn more about the specifics of this lawsuit, the following details provide further insight.
Key Takeaways
- A lawsuit alleges that GlaxoSmithKline engaged in anticompetitive practices to block generic competition for its Breo Ellipta drug by retiring branded inhalers and replacing them with follow-on products.
- The lawsuit claims that GlaxoSmithKline’s “device hopping” tactics extended patent and regulatory exclusivity, allowing the company to charge artificially inflated prices.
- The lawsuit seeks a jury verdict that GlaxoSmithKline’s actions were anticompetitive and resulted in overcharges passed on to consumers.
- Breo Ellipta is a combination inhaler approved by the FDA in 2013 for COPD and 2015 for asthma, with active ingredients of vilanterol trifenate and fluticasone furoate.
- Potential side effects of Breo Ellipta include corticosteroid excess, high blood sugar, thrush, and increased pneumonia risk.
Breo Ellipta Overview
The Breo Ellipta is a combination inhaler developed by GlaxoSmithKline Plc. and Theravance, Inc. to treat both asthma and chronic obstructive pulmonary disease (COPD). Approved by the FDA in 2013 for COPD and 2015 for asthma, Breo Ellipta contains the active ingredients vilanterol trifenate and fluticasone furoate.
Available in two dosage strengths, Breo Ellipta is used to treat pulmonary conditions like COPD and asthma. Potential side effects include signs of excessive corticosteroid, high blood sugar, thrush, and increased pneumonia risk.
FDA Approval
Breo Ellipta received FDA approval in May 2013 for the treatment of chronic obstructive pulmonary disease (COPD) and in April 2015 for the treatment of asthma. The FDA’s approval was based on 4 confirmatory trials enrolling 7,700 patients with moderate to severe COPD.
Breo Ellipta’s approval was supported by the FDA’s advisory committee, which voted 9-4 in favor of its administration for COPD. The FDA’s approval was based on Breo Ellipta’s active ingredients, fluticasone furoate and vilanterol, which have unique properties compared to other corticosteroids and beta-agonists.
The recommended dosage depends on the severity of the patient’s condition, starting at 100 mcg fluticasone furoate and 25 mcg vilanterol for COPD and asthma.
Uniqueness of Product
Since Breo Ellipta‘s active ingredients, fluticasone furoate and vilanterol, possess unique properties compared to other corticosteroids and beta-agonists, the product offers distinct therapeutic advantages. Fluticasone furoate has 1.7 times higher binding similarity to human glucocorticoid receptors than fluticasone propionate, suggesting greater potency.
Vilanterol has similar functional selectivity to salmeterol xinafoate, targeting beta2-receptors predominant in bronchial smooth muscle. The combination of these active ingredients leads to increased cAMP levels, causing bronchial muscle relaxation and inhibition of hypersensitivity mediator release, making Breo Ellipta an effective treatment for chronic obstructive pulmonary disease (COPD).
Breo Ellipta Dosage and Administration, Warnings, and Contraindications
Recommended dosages for Breo Ellipta, a combination medication containing fluticasone furoate and vilanterol, vary based on the indicated condition. The standard dose for COPD and asthma is 100/25 mcg, with a higher 200/25 mcg strength for some asthma patients. Dose adjustments aren’t needed for renal/hepatic impairment or geriatrics.
Breo Ellipta shouldn’t be used for acute bronchospasm or as primary treatment for acute asthma/COPD episodes. Potential side effects include excessive corticosteroid, high blood sugar, thrush, worsening COPD, glaucoma, and cardiovascular issues. Breo Ellipta is contraindicated for those with severe milk protein allergies or demonstrated hypersensitivity to its ingredients.
The Breo Ellipta lawsuit may focus on these warnings and contraindications within the district’s clinical trials.
Potential Side Effects and Risks of Breo Ellipta
Breo Ellipta can cause concerning side effects like elevated blood sugar, fungal infections, and cardiovascular issues including increased blood pressure and pulse rate. These risks may be especially pronounced with large doses or excessive use of the medication.
Patients should be aware of these potential side effects and closely monitor their condition while taking Breo Ellipta.
Elevated Blood Sugar
Prolonged use of the corticosteroid component in Breo Ellipta can lead to signs of too much corticosteroid, including elevated blood sugar levels. Patients using Breo Ellipta should monitor for symptoms of high blood sugar and report them to their healthcare provider.
This elevated blood sugar risk is a known potential side effect associated with the corticosteroid fluticasone furoate in Breo Ellipta. Patients with diabetes or at risk of diabetes should be closely monitored when using Breo Ellipta due to this increased blood sugar side effect.
Healthcare providers should consider the risk of elevated blood sugar when prescribing Breo Ellipta, particularly for patients with conditions affecting blood sugar levels. GlaxoSmithKline LLC, the manufacturer of Breo Ellipta, has faced billion-dollar lawsuits in the U.S. over health issues related to their drugs.
Fungal Infections
Perhaps you’ve noticed an unusual taste or discomfort in your mouth while using Breo Ellipta. This may be a sign of thrush or oral candidiasis, a potential side effect.
Breo Ellipta can increase the risk of fungal infections in the mouth and throat for some patients. Long-term use of the inhaled corticosteroid fluticasone furoate in Breo Ellipta may also heighten the risk of fungal infections.
Patients should be monitored for these issues and promptly treated if they occur. Fungal infections are among the potential risks that have led to Breo Ellipta lawsuits filed in district courts across the country.
Cardiovascular Effects
Cardiovascular complications can arise from the use of Breo Ellipta. The active ingredient vilanterol can increase blood pressure and heart rate.
Additionally, QTc interval prolongation and ventricular arrhythmias have been associated with large doses or excessive use of Breo Ellipta. Data suggests long-acting beta-agonists like vilanterol may increase the risk of asthma-related deaths. Patients taking Breo Ellipta should be closely monitored for cardiovascular side effects.
These concerns have led to lawsuits filed in the District of Delaware over the safety of Breo Ellipta.
Lawsuit Overview
The proposed class-action lawsuit alleges that GlaxoSmithKline (GSK) engaged in an anticompetitive scheme to block generic competition for its asthma inhalers, including Breo Ellipta. The lawsuit claims GSK’s “device hopping” tactics extended patent and regulatory exclusivity, allowing it to charge “artificially inflated prices” for over 60 years on the Ventolin inhaler and over 35 years on the Flovent and Arnuity Ellipta inhalers.
The plaintiff, who paid for the Ventolin and Arnuity Ellipta inhalers, alleges GSK “schemed” the FDA approval system, creating a “moving target” for generic makers. The lawsuit seeks a jury verdict that GSK’s actions were anticompetitive, resulting in overcharges passed on to consumers.
GSK’s Asthma Inhaler Products
GlaxoSmithKline’s asthma inhaler products include the Ventolin, Flovent, and Arnuity Ellipta inhalers. Ventolin is a short-acting beta-agonist used to treat asthma symptoms. Flovent is a corticosteroid inhaler for long-term asthma management. Arnuity Ellipta combines a corticosteroid and long-acting beta-agonist. These products are protected by GlaxoSmithKline’s intellectual property rights.
The company has faced lawsuits over alleged anti-competitive practices to maintain market dominance for its asthma inhalers. Disputes over intellectual property can arise as branded drugs lose patent exclusivity and generic competitors seek to enter the market.
Alleged Anticompetitive Practices
GSK allegedly engaged in an anticompetitive scheme to maintain long-term protection for its asthma inhalers. This scheme involved retiring branded inhalers, replacing them with follow-on products granted new patents and regulatory protection, and blocking generic competition. The alleged practices are claimed to have allowed GSK to charge artificially inflated prices that patients had to pay.
Retiring Branded Inhalers
According to the lawsuit, GlaxoSmithKline (GSK) allegedly engaged in an anticompetitive scheme to block generic competition by retiring branded inhalers like Ventolin and Flovent and replacing them with follow-on products granted new patents and regulatory protection. This “device hopping” scheme allowed GSK to extend its exclusivity for over 60 years for Ventolin and over 35 years for Flovent, which resulted in artificially inflated prices for consumers.
The lawsuit accuses GSK of “schemed the FDA drug-device approval system” to create a “moving target” for generic competitors, forcing patients to “foot the bill” for the inflated prices.
New Product Patents
Allegedly, the pharmaceutical company employed a strategic maneuver to extend exclusivity for its branded asthma inhalers by securing new patents on follow-on products. This allowed GSK to maintain a monopoly by blocking and delaying the entry of competing generic inhalers for decades.
The new product patents granted additional regulatory protection periods, resulting in over 60 years of uninterrupted protection for Ventolin and over 35 years for Flovent and Arnuity Ellipta. This allegedly enabled GSK to charge “artificially inflated prices” and force patients to “foot the bill” for decades-old products that account for a significant portion of total retail spending on prescription drugs.
Blocking Generic Competition
The alleged anticompetitive scheme utilized by the pharmaceutical company is said to have allowed it to extend exclusivity for its branded asthma inhalers by securing new patents on follow-on products. This reportedly enabled over 60 years of uninterrupted protection for its Ventolin inhaler and over 35 years for its Flovent and Arnuity Ellipta inhalers.
The lawsuit claims this “device hopping” strategy was designed to block and delay generic competition, forcing patients to pay artificially inflated prices. This alleged “moving target” approach to the FDA drug-device approval system is recognized as a significant public health concern due to the high cost of the company’s asthma inhalers.
Is the Breo Ellipta Lawsuit Similar to Karoline Leavitt’s Lawsuit Against The View?
The Breo Ellipta lawsuit highlights issues of product liability and safety, while karoline leavitt’s legal battle with the view centers on workplace discrimination. Both cases reflect struggles against perceived injustices, but they emerge from vastly different contexts—one involving a medical device, the other a media environment.
Impact on Patients
The high cost of asthma inhalers has placed a significant burden on patients, forcing them to “foot the bill” for artificially inflated prices. According to the lawsuit, GSK’s anticompetitive practices, including “device hopping,” resulted in over 60 years of uninterrupted protection for its Ventolin inhaler line, limiting patient access to more affordable generic alternatives.
This has led to decades-old asthma inhalers accounting for 5% of total net retail spending on prescription drugs in the U.S., recognized as a significant public health concern. The lawsuit alleges that GSK’s scheme to extend patent and regulatory exclusivity has forced patients to bear the cost of these artificially high prices.
Regulatory Concerns
The lawsuit alleges that GSK exploited the FDA’s drug-device approval system, leaving generic competitors chasing a “moving target” for over half a century.
This regulatory complexity has been recognized as a significant public health concern in the U.S., as it has delayed the entry of competing inhalers and contributed to the high costs of these essential medications.
Exploits Drug Approval System
Reportedly, the Breo Ellipta lawsuit alleges that GlaxoSmithKline (GSK) exploited the drug-device approval system to maintain a monopoly on its asthma inhalers. The lawsuit claims GSK engaged in “device hopping” by retiring branded inhalers and replacing them with follow-on products granted new patents and regulatory protection.
This allowed GSK to charge “artificially inflated prices” for its inhalers. The lawsuit argues this anticompetitive practice has resulted in decades-old asthma inhalers accounting for a significant portion of total net retail spending on prescription drugs, becoming a public health concern in the U.S.
Generics Lack Regulatory Clarity
According to the lawsuit, GSK’s alleged “device hopping” strategy has created a “moving target” for generic manufacturers, posing significant regulatory concerns. The lawsuit contends that GSK has leveraged the FDA’s drug-device approval system to prolong the exclusivity of its asthma inhaler products, which has resulted in a lack of regulatory clarity for generic competitors.
This has allowed GSK to block and delay the entry of competing generic inhalers for over half a century, denying patients access to more affordable treatment options. The lawsuit argues that GSK’s anticompetitive practices have deprived the public of the benefits of a competitive market for asthma inhalers.
Conclusion
You may have heard the allegations that GlaxoSmithKline engaged in anticompetitive practices to maintain its monopoly on Breo Ellipta. While the facts remain unclear, the impact on patients could be significant. If true, these actions may have denied access to more affordable treatment options, compromising the health and well-being of those who rely on this medication. The truth behind these claims warrants further investigation to protect the interests of consumers.
